This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up. per 100 person-year.
Random-effects meta-analyses examined the pooled risk difference in the prevalence of each symptom or symptom combination in cases with confirmed SARS-coV-2 infection compared with controls.ResultsEight cohort studies were eligible, including nearly 10 million people.
Stroke, Ahead of Print. Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes. The clinical presentation of cerebral venous thrombosis is diverse (eg, headaches, seizures), requiring a high level of clinical suspicion. The clinical course of cerebral venous thrombosis may be difficult to predict.
DALLAS, January 29, 2024 — A new scientific statement from the American Heart Association emphasizes the need to increase patients’ and physicians’ awareness of cerebral venous thrombosis (CVT) to improve the recognition of this condition and initiate.
New research has shown that over the long-term, standing more compared with sitting does not improve cardiovascular health (coronary heart disease, stroke and heart failure), and could increase the risk of circulatory issues related to standing, such as varicose veins and deep vein thrombosis.
Humans and mice exposed to long-wavelength red light had lower rates of blood clots that can cause heart attacks, lung damage and strokes, according to research led by University of Pittsburgh School of Medicine and UPMC surgeon-scientists and published today in the Journal of Thrombosis and Haemostasis.
The left atrial appendage dangles off the left atrial chamber in the heart and has long been suspected of being a nidus for clot that can break off and cause a stroke. In a prior age, there were no good options for these patients, and doctors and families were reduced to prayer to prevent strokes from occurring.
Patients were evaluated based on a composite outcome of all-cause mortality, stroke, or myocardial infarction. Bioprosthetic valve dysfunction (BVD) was categorized into structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis, or endocarditis. Severe SVD was defined by specific criteria.
Stroke, Volume 55, Issue Suppl_1 , Page AWP227-AWP227, February 1, 2024. Introduction:Deep medullary vein(DMV) thrombosis is a rare cause of neurological damage noted in both term and preterm infants. The spectrum of parenchymal radiological findings in DMV thrombosis includes edema and hemorrhage of variable extent.
Stroke, Volume 56, Issue Suppl_1 , Page AWP143-AWP143, February 1, 2025. Introduction:The majority of patients with cerebral venous thrombosis (CVT) achieve functional independence (modified Rankin Score [mRS] 0-2), although many continue to experience residual symptoms that negatively impact quality of life. female, 74.7% white race).
Stroke, Volume 56, Issue Suppl_1 , Page ATP268-ATP268, February 1, 2025. Introduction:Xylitol, a sugar alcohol with a global market estimated at 161,500 metric tons, has been linked to increased thrombosis and risk of stroke and heart attack. The mean BMI was 35.2 kg/m2, HbA1c was 5.9% 0.4,
Stroke, Ahead of Print. We sought to explore the relationship between ART and stroke risk using population-level data.Methods:We conducted a retrospective cohort study using data from the National Inpatient Sample (NIS) registry from 2015-2020, including all delivery hospitalizations for patients aged 15-55 years. 100,000 vs. 9.1/100,000),
Introduction:Subclinical leaflet thrombosis is an increasingly recognized complication in patients undergoing transcatheter aortic valve replacement (TAVR). Patients with hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RELM) have a higher incidence of strokes and transient ischemic attacks.
The study found no significant difference in death or disabling stroke between TAVR and SAVR patients (HR 1.02, 95% CI 0.93–1.11, 1.11, p=0.70) with similar long-term mortality risks. Notably, on a prespecified analysis, the study addressed the outcomes of two distinct TAVR devices versus SAVR.
Stroke, Volume 56, Issue Suppl_1 , Page AWP299-AWP299, February 1, 2025. Background:Newer Oral Anticoagulants (NOACs) offer potential advantages for patients with cerebral venous sinus thrombosis (CVST). However, there is a lack of evidence to evaluate the efficacy and safety of NOACs in CVST. vs 8.0%, P=0.014) and mRS2 (95.1%
The comorbidity of HF and stroke is a high risk condition that requires particular attention to ensure early detection of complications, efficient diagnostic workup, close monitoring, and consequent treatment of the patient. Beside the physicians perspective, also the patients values and preferences are taken into account.
Stroke, Ahead of Print. Ischemic stroke is one of the leading causes of disability and mortality worldwide. Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionCerebral venous sinus thrombosis (CVST) is a rare form of stroke that usually affects young females especially during pregnancy and the postpartum period.
Stroke, Volume 55, Issue Suppl_1 , Page ATP180-ATP180, February 1, 2024. Background:Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%.
These included three cases of intraoperative thrombosis, three instances of pericardial effusion or tamponade, one case of device-related thrombosis, one peri-device leak, one systemic embolism, one bleeding episode, and one additional device-related complication.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP62-ATMP62, February 1, 2024. Introduction:Seizures are a common initial manifestation of cerebral venous thrombosis (CVT). The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. Univariate analysis was performed using Chi-square, rank-sum, and t-tests.
Stroke, Volume 55, Issue 2 , Page 311-323, February 1, 2024. Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide. In addition to stroke, ICAD increases the risk of dementia and cognitive decline, magnifying ICAD societal burden.
Stroke, Volume 55, Issue Suppl_1 , Page AWMP59-AWMP59, February 1, 2024. Background:Information on long-term care utilization patterns following the acute care period of cerebral venous thrombosis (CVT) is limited. The most common neurologic reasons for readmission differed by age group, but included headaches, seizures, and stroke.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP96-ATMP96, February 1, 2025. Introduction:Pediatric arterial ischemic stroke (AIS) affects 1-2 per 100,000 children. Patients treated for concomitant venous thrombosis and/or without follow up imaging were excluded. Data was de-identified and SAS 8.3 was used for analysis.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionCerebral sinus venous thrombosis (CSVT) has traditionally been treated medically with systemic anticoagulation. Recent advances in endovascular therapy (EVT) may represent an alternative treatment to medical therapy for CSVT.
Stroke, Volume 55, Issue Suppl_1 , Page AWP260-AWP260, February 1, 2024. Background:Cerebral venous thrombosis (CVT) is associated with significant risk of death and disability.
Stroke, Volume 55, Issue Suppl_1 , Page ATP7-ATP7, February 1, 2024. Our findings highlight the potential of conservative care for ruptured spinal artery aneurysms, with spontaneous thrombosis demonstrated on short-term follow-up angiograms. While morbidity and mortality seem low, limited data makes generalizations difficult.
Stroke, Volume 56, Issue Suppl_1 , Page A151-A151, February 1, 2025. Introduction:Stroke is a leading cause of maternal morbidity and mortality, and the incidence of maternal stroke is triple that of age-matched, non-pregnant counterparts. Characteristics of the study population are shown in the Table.
Stroke, Volume 56, Issue Suppl_1 , Page AWP355-AWP355, February 1, 2025. Stroke outcomes were assessed at 24 hours.Results:Exposure to long wavelength red light resulted in a significant reduction in infarct volume following stroke (mice-red 38.817.6 The change in thrombosis only occurred when mice were pre-exposed to red light.
Stroke, Volume 55, Issue Suppl_1 , Page ATP267-ATP267, February 1, 2024. Introduction:Exposure to high altitude environment is a risk factor of cerebral venous thrombosis (CVT) probably due to the hypercoagulability.
These results suggest that abelacimab may be safe across the spectrum of bleeding risk and may make it possible to anticoagulate some of the most vulnerable populations who otherwise would not be treated and therefore left unprotected from the risk of stroke. Data from these trials are expected in the second half of 2026.
Stroke, Volume 55, Issue Suppl_1 , Page AWP149-AWP149, February 1, 2024. Background:Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). The optimal transition strategy from parenteral anticoagulation (PA) to DOAC is not known.
Stroke-volume:50 ml. MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. Left ventricular end-diastolic volume: 99 ml.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP16-ATMP16, February 1, 2025. Elevated levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP117-ATMP117, February 1, 2024. Stroke is a serious complication of diabetes. Earlier, we demonstrated that exposure to single hypoglycemia (SH), 5-day RH (once every day), and twice-a-week RH for 6 weeks increases stroke risk in male insulin-treated diabetic (ITD) rats.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP117-ATMP117, February 1, 2025. Introduction:Despite timely recanalization, some ischemic stroke patients treated with endovascular thrombectomy experience persistent neurological deterioration. Experimental stroke models have indicated a critical role for platelets in this process.
Stroke, Volume 56, Issue Suppl_1 , Page ATP67-ATP67, February 1, 2025. Introduction:Ongoing staff stroke education is crucial to ensure that stroke knowledge remains current and at the forefront of everyone's minds and is also required for stroke certification.
Stroke, Volume 56, Issue Suppl_1 , Page AWP134-AWP134, February 1, 2025. Introduction:Stroke is a leading cause of maternal morbidity and mortality, and hemorrhagic strokes account for up to half of these cases. Prior studies in non-maternal populations demonstrated that 9% of strokes are missed at initial ED presentation.
Stroke, Volume 56, Issue 2 , Page 527-532, February 1, 2025. BACKGROUND:Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP59-AWMP59, February 1, 2025. Background and Purpose:External counterpulsation (ECP) is a novel noninvasive method used to improve the perfusion of vital organs, which may benefit ischemic stroke patients. of 65 patients in ECP group compared to 9.1%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content